The estimated Net Worth of Youssef El Zein is at least $1.2 millió dollars as of 3 October 2016. Youssef Zein owns over 4,228 units of Idera Pharmaceuticals stock worth over $222,264 and over the last 17 years Youssef sold IDRA stock worth over $974,416.
Youssef has made over 19 trades of the Idera Pharmaceuticals stock since 2008, according to the Form 4 filled with the SEC. Most recently Youssef bought 4,228 units of IDRA stock worth $10,824 on 3 October 2016.
The largest trade Youssef's ever made was exercising 279,727 units of Idera Pharmaceuticals stock on 29 May 2008 worth over $2,237,816. On average, Youssef trades about 13,973 units every 58 days since 2008. As of 3 October 2016 Youssef still owns at least 516,892 units of Idera Pharmaceuticals stock.
You can see the complete history of Youssef Zein stock trades at the bottom of the page.
Youssef's mailing address filed with the SEC is C/O IDERA PHARMACEUTICALS, INC., 167 SIDNEY STREET, CAMBRIDGE, MA, 02139.
Over the last 17 years, insiders at Idera Pharmaceuticals have traded over $20,746,904 worth of Idera Pharmaceuticals stock and bought 38,459,430 units worth $53,771,070 . The most active insiders traders include Bros. Advisors Lp14159, L.P..., Bros. Advisors Lp Baker Bro... és Invest Corp Pillar Pharmace.... On average, Idera Pharmaceuticals executives and independent directors trade stock every 43 days with the average trade being worth of $309,429. The most recent stock trade was executed by John J. Kirby on 17 December 2021, trading 10,000 units of IDRA stock currently worth $6,200.
Harnessing the approach of the earliest researchers in immunotherapy and the company's vast experience in developing proprietary immunology platforms, Idera's development program is focused on priming the immune system to play a more powerful role in fighting cancer, ultimately increasing the number of people who can benefit from immunotherapy. Idera also continues to focus on the acquisition, development, and ultimate commercialization of drug candidates for both oncology and rare disease indications characterized by small, well-defined patient populations with serious unmet needs.
Idera Pharmaceuticals executives and other stock owners filed with the SEC include: